As of January 2018, Gilead has raised the price of its HIV/AIDS treatments Truvada, Genvoya and Descovy 6.9%, despite the fact that the patent for tenofovir, a key component of …
As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada
Ethically challenged drug company has made billions off the drug since its initial FDA approval while it simultaneously sought to ‘evergreen’ and manipulate patent extension process LOS ANGELES (October 17, …
AHF to Appeal Gilead AIDS Drug Patent Case
In January, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding slightly different formulations of tenofovir, a key …
Fierce Pharma: Planes, hearses and caravans dot ‘Gilead Greed Kills!’ protests from AIDS foundation
By Carly Helfand | FiercePharma | Jun 16, 2016 The Los Angeles-based AIDS Healthcare Foundation has already sued Gilead Sciences and asked lawmakers to investigate the company over its drug pricing. …
AHF’s ‘Gilead Greed Kills!’ Protest Continues Shaming of AIDS & Hepatitis C Drug Maker over Pricing & Policies
Lunchtime protest today in front of Gilead headquarters in Foster City, CA expands drug price advocacy campaign by bringing the message home to company’s employees and executives. LOS ANGELES (June …
